Takeda

GenAhead said it will use the IP it had licensed from ERS for genome editing applications in pharmaceutical drug discovery and development.

The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.

Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.

HudsonAlpha researchers are expected to sequence 20,000 patient tumor and non-tumor samples for ORIEN's Avatar initiative by 2019.

The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.

The Avatar Research Program will collect de-identified genomic and clinical information from consenting patients treated at ORIEN cancer centers.

The partners will screen for molecules that could revive metabolic activity in heart tissue damaged by cardiovascular disease or failure.

NEW YORK (GenomeWeb) – Using a new in-phase assay, researchers led by Duke University's Allen Roses believe they have captured key differences in APOE and TOMM40 haplotypes between African-American, Caucasian, and West African populations.

Seattle Genetics will receive a $6 million milestone payment from Takeda Pharmaceutical after the first commercial sales of Adcetris in Australia, South Korea, and Mexico.

This is the first of a two-part feature on the state of personalized drug development. The first part focuses on the scientific challenges facing the industry. The second part discusses the evolving regulatory and financial environment and recent advances in the field.

Pages

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.